NCT06822010View on ClinicalTrials.gov

SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

April 1, 2028

Study Completion Date

April 1, 2029

Conditions
Urinary Bladder CancerUpper Tract Urothelial CancerUrothelial Cancer
Interventions
DRUG

Sequential Gemcitabine and Jelmyto Treatment (Gem/Jel)

"Drug: Gemcitabine (endoluminal administration)~Drug: Jelmyto (gel-based mitomycin, endoluminal administration)"

All Listed Sponsors
lead

Rutgers, The State University of New Jersey

OTHER